Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02424019 · ClinicalTrials.gov registry record · Phase 4
Phase 4 IOP Signals Associated With ILUVIEN®
A Phase 4 study, sponsored by Alimera Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 153
- Enrollment target
NCT02424019 is a Phase 4 study that has completed, run by Alimera Sciences. The registered enrollment target is 153 participants.
The verdict
NCT02424019, a Phase 4 study, has completed, sponsored by Alimera Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 153 participants
- Enrollment target
Study Summary
This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.
Interventions
- DRUG ILUVIEN 0.19 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2015-05-06 |
| Est. Completion | 2020-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02424019
The ClinicalTrials.gov registry entry for NCT02424019 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alimera Sciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ILUVIEN 0.19 MG is the first listed.
NCT02424019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02424019 about?
NCT02424019 is a clinical study titled "Phase 4 IOP Signals Associated With ILUVIEN®". This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.
What is the current status of trial NCT02424019?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 153 participants. The study started on 2015-05-06. Estimated completion is 2020-07-31.
What interventions are being tested in trial NCT02424019?
The interventions under investigation include: ILUVIEN 0.19 MG (DRUG).
Who is sponsoring clinical trial NCT02424019?
This trial is sponsored by Alimera Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.